Many a rheumatology consult has centered on a perplexing question: Does this patient have central nervous system (CNS) vasculitis? At the 2021 ACR State-of-the-Art Clinical Symposium, Rula Hajj-Ali, MD, FACP, professor of medicine and associate director of vasculitis care and research, Cleveland Clinic Lerner College of Medicine, discussed this topic in detail, providing a series…
In spring 2020, as it became obvious that COVID-19 wasn’t going anywhere anytime soon, the leaders of the Rheumatology Research Foundation implemented an expedited process to distribute research funding beyond its typical awards program. This resulted in the Foundation awarding $1.65 million to fund five research studies that will look at the relationships between rheumatic…
The Budget Control Act of 2011 cut Medicare physician payments by 2% across the board. The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law in 2020, suspended this sequester (i.e., a cut in government spending) between May 1 and Dec. 31, 2020. In the Consolidated Appropriations Act, signed into law in December…
A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…
In a randomized, controlled trial, the risk difference between groups is interpreted as a causal effect of the treatment, according to Seoyoung C. Kim, MD, ScD, MSCE, an associate professor of medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital and Harvard Medical…
The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…
The new Twitter account enables quick communication between ACR advocacy staff and ACR/ARP members about the policies, regulations and legislation that affect rheumatology patients and providers and how members can get involved.
At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.
The ACR is advocating against policies that threaten patient access and disrupt practice workflow, including non-medical switching, tapering patients off biologics, specialty pharmacy acquisition mandates and site-of-service restrictions.
Bright spots from this legislative session include utilization management reform, copay accumulator bans and pharmacy benefit manager reform.